116 related articles for article (PubMed ID: 1623689)
41. Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.
Motzer RJ; Nanus DM; O'Moore P; Scher HI; Bajorin DF; Reuter V; Tong WP; Iversen J; Louison C; Albino AP
Cancer Res; 1992 Oct; 52(20):5775-9. PubMed ID: 1394202
[TBL] [Abstract][Full Text] [Related]
42. A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.
Gradishar WJ; Soff G; Liu J; Cisneros A; French S; Rademaker A; Benson AB; Bouck N
Oncology; 2000 May; 58(4):324-33. PubMed ID: 10838499
[TBL] [Abstract][Full Text] [Related]
43. Suramin, a novel antitumor compound.
La Rocca RV; Stein CA; Danesi R; Myers CE
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):893-8. PubMed ID: 2285603
[TBL] [Abstract][Full Text] [Related]
44. Anaphylactoid reaction with suramin.
Thibault A; Figg WD; Cooper MR; Prindiville SA; Sartor AO; Headlee DJ; Myers CE
Pharmacotherapy; 1993; 13(6):656-7. PubMed ID: 8302692
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of intravenous rifampicin (rifampin) in neonates.
Pullen J; Stolk LM; Degraeuwe PL; van Tiel FH; Neef C; Zimmermann LJ
Ther Drug Monit; 2006 Oct; 28(5):654-61. PubMed ID: 17038881
[TBL] [Abstract][Full Text] [Related]
46. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
47. Postoperative complications in patients receiving suramin therapy.
Cole DJ; Ettinghausen SE; Pass HI; Danforth DN; Linehan MW; Myers CW; Cooper MR; Sindelar WF
Surgery; 1994 Jul; 116(1):90-5. PubMed ID: 8023275
[TBL] [Abstract][Full Text] [Related]
48. Optimising antimicrobial therapy through the use of Bayesian dosing programs.
Avent ML; Rogers BA
Int J Clin Pharm; 2019 Oct; 41(5):1121-1130. PubMed ID: 31392582
[TBL] [Abstract][Full Text] [Related]
49. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
50. Suramin keratopathy.
Holland EJ; Stein CA; Palestine AG; LaRocca R; Chan CC; Kuwabara T; Myers CE; Thomas R; McAtee N; Nussenblatt RN
Am J Ophthalmol; 1988 Aug; 106(2):216-20. PubMed ID: 3400766
[TBL] [Abstract][Full Text] [Related]
51. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect.
La Rocca RV; Stein CA; Danesi R; Jamis-Dow CA; Weiss GH; Myers CE
J Clin Endocrinol Metab; 1990 Aug; 71(2):497-504. PubMed ID: 2380344
[TBL] [Abstract][Full Text] [Related]
52. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
Fukuhara K; Ikawa K; Morikawa N; Kumagai K
J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
[TBL] [Abstract][Full Text] [Related]
53. Suramin: the discovery of an old anticancer drug.
Zaniboni A
Med Oncol Tumor Pharmacother; 1990; 7(4):287-90. PubMed ID: 2283894
[TBL] [Abstract][Full Text] [Related]
54. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
Loh GW; Ting LS; Ensom MH
Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
56. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
57. The effect of suramin on laboratory tests of coagulation.
Horne MK; Wilson OJ; Cooper M; Gralnick HR; Myers CE
Thromb Haemost; 1992 Apr; 67(4):434-9. PubMed ID: 1631791
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin.
de Souza OF; Sakamoto T; Kimura H; Koda RP; Gabrielian K; Spee C; Ryan SJ
Ophthalmologica; 1995; 209(4):212-6. PubMed ID: 8545096
[TBL] [Abstract][Full Text] [Related]
59. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.
Rousseau A; Sabot C; Delepine N; Delepine G; Debord J; Lachâtre G; Marquet P
Clin Pharmacokinet; 2002; 41(13):1095-104. PubMed ID: 12403645
[TBL] [Abstract][Full Text] [Related]
60. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
